EP08.01-059 Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer

Abstract

Immune checkpoint therapies have revolutionized the therapy of metastatic Non-Small Cell Lung Cancer (mNSCLC), leading to durable therapeutic responses not typically seen with traditional cytotoxic anti-cancer agents. However, primary and acquired resistance to anti-PD-(L)1 therapy impacts the majority of the patients, and new strategies are investigated to prevent or reverse resistance to therapy. Here we present clinical safety and early efficacy data of the combination of Pembrolizumab with a first in class, oral selective inhibitor of nuclear export, Selinexor in mNSCLC.